← Leaderboards
Stephen I. Pelton
Boston University Medical Campus
$1,352,372
Attributed
$1,597,122
Total exposure
18
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $274.3K · FY2005–23$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,597,122 · 18
By mechanism
R21$968,000 · 2
M01$629,122 · 16
Top collaborators
- Tianhong Dai2 shared
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsClinical ResearchHuman SubjectPediatric AidsChild (0-11)Human Therapy EvaluationAids TherapyChildClinical TrialsPediatric PharmacologyHaemophilus InfluenzaeOutcomes ResearchPathogenMedical ComplicationIn VitroMicrobial BiofilmsAntimicrobialChinchilla (Genus)AnimalsImmunogenicityMediatingEffectivenessCombination ChemotherapyMiddle Ear
Grant awards (26)
"Optical Tympanostomy Tube" for prevention and treatment of tympanostomy tube otorrhea$215,250
R21 · FY2023 · DC
"Optical Tympanostomy Tube" for prevention and treatment of tympanostomy tube otorrhea$274,250
R21 · FY2022 · DC
Single Antigen Strategy for Prevention of Recurrent and Chronic Suppurative Otitis$217,500
R21 · FY2016 · DC · contact PI
Single Antigen Strategy for Prevention of Recurrent and Chronic Suppurative Otitis$261,000
R21 · FY2015 · DC · contact PI
LATE OUTCOMES OF PEDIATRIC HIV INFECTION (PACTG 219C VERSION 40)$119,834
M01 · FY2007 · RR · contact PI
SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN PAPILLOMAVIRUS$4,317
M01 · FY2007 · RR · contact PI
RANDOMIZED TRIAL OF THE SAFETY AND IMMUNOGENICITY OF FLUMIST IN HIV INF CHILDREN$2,160
M01 · FY2007 · RR · contact PI
LATE OUTCOMES OF PEDIATRIC HIV INFECTION (PACTG 219C VERSION 40)$143,099
M01 · FY2006 · RR · contact PI
RANDOMIZED TRIAL OF THE SAFETY AND IMMUNOGENICITY OF FLUMIST IN HIV INF CHILDREN$13,108
M01 · FY2006 · RR · contact PI
ULTRASOUND EVAL OF FLOW RELATED ARTERIAL DILATION IN HIV INFECTED CHILDREN$6,554
M01 · FY2006 · RR · contact PI
IMMUNOGENICITY OF LIVE ATTENUATED VARICELLA VACCINE HIV INFECTED CHILDREN$1,091
M01 · FY2006 · RR · contact PI
LATE OUTCOMES OF PEDIATRIC HIV INFECTION (PACTG 219C VERSION 40)$95,005
M01 · FY2005 · RR
ULTRASOUND EVAL OF FLOW RELATED ARTERIAL DILATION IN HIV INFECTED CHILDREN$18,333
M01 · FY2005 · RR
RANDOMIZED TRIAL OF THE SAFETY AND IMMUNOGENICITY OF FLUMIST IN HIV INF CHILDREN$13,333
M01 · FY2005 · RR
IMMUNOGENICITY OF LIVE ATTENUATED VARICELLA VACCINE HIV INFECTED CHILDREN$1,668
M01 · FY2005 · RR
Late Outcomes of Pediatric HIV Infection (PACTG 219C Version 4.0)$83,243
M01 · FY2004 · RR
Immunogenicity of Pneumococcal Conjugate Vaccine$5,429
M01 · FY2004 · RR
ACTG 265--IMMUNOGENICITY OF ATTENUATED VARICELLA VACCINE IN HIV+ CHILDREN$0
M01 · FY2001 · RR
ABT 378/RITONAVIR WITH REVERSE TRANSCRIPTASE INHIBITORS IN HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
ACTG 338--ANTIRETROVIRAL THERAPY IN STABLE EXPERIENCED HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
ACTG 219--LATE OUTCOMES OF PEDIATRIC HIV INFECTION$0
M01 · FY2001 · RR
AT/AZ AS COMPARED TO TMP/SMX IN PREVENTING BATERIAL INFECTION$30,487
M01 · FY2000 · RR
ACTG 219--LATE OUTCOMES OF PEDIATRIC HIV INFECTION$30,487
M01 · FY2000 · RR
ACTG 338--ANTIRETROVIRAL THERAPY IN STABLE EXPERIENCED HIV INFECTED CHILDREN$30,487
M01 · FY2000 · RR
ACTG 265--IMMUNOGENICITY OF ATTENUATED VARICELLA VACCINE IN HIV+ CHILDREN$30,487
M01 · FY2000 · RR
ABT 378/RITONAVIR W/ REVERSE TRANSCRIPTASE INHIB IN HIV$0
M01 · FY2000 · RR